Αποτελέσματα Αναζήτησης
6 Μαΐ 2024 · Glioblastoma multiforme (GBM) is the most malignant and pervasive subtype of glioma and is the most common primary brain tumor in adults. It remains an incurable disease with a median survival of 15 months and has been classified into wild-type and mutant isocitrate dehydrogenase (IDH) subtypes.
15 Ιουλ 2020 · Meta-analyses of real-world data suggested a doubling of 2- and 3-year survival in glioblastoma patients since 2005. However, 5-year survival remains poor with no apparent improvement.
Glioblastoma multiforme (GBM) is a WHO grade IV glioma and the most common malignant, primary brain tumor with a 5-year survival of 7.2%. Its highly infiltrative nature, genetic heterogeneity, and protection by the blood brain barrier (BBB) have posed great treatment challenges.
19 Ιουν 2019 · Factors associated with odds of improved 5-year overall survival in multivariable analysis were younger age, female sex, less medical comorbidities, nonwhite race, highest median income quartile, left-sided tumors and tumors outside the brainstem, and treatment with radiotherapy (P <.05 for all).
Glioblastoma multiforme (GBM) is an aggressive primary brain tumor with most dismal survival rates. This study aims to examine the prognostic value of primary tumor sites and race on survival outcomes. Methods.
15 Δεκ 2015 · Over the last decade, the approach to the management of brain tumours and the understanding of glioblastoma tumour biology has advanced and a number of therapeutic interventions have evolved,...
Amongst all cancers, the diagnosis of glioblastoma multiforme (GBM) portends one of the most malevolent clinical prognoses. Median survival is only nine months, rising to 15–16 months for those receiving standard of care surgery and adjuvant chemoradiation. 1–3
